CLEVELAND–Scientists from the Case Western Reserve University digital imaging lab, already pioneering the use of Artificial Intelligence (AI) to predict whether chemotherapy will be successful, can now determine which lung-cancer patients will benefit from expensive immunotherapy. And, once again, they're doing it by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy treatment. And, as with previous work, those changes have been discovered both inside–and outside–the tumor, a signature of the lab's recent research. "This is no flash in the pan–this research really seems to be reflecting something about the very biology of the disease, about which is the more aggressive phenotype, and that's information oncologists do not currently have," said Anant Madabhushi, whose Center for Computational Imaging and Personalized Diagnostics (CCIPD) has become a global leader in the detection, diagnosis and characterization of various cancers and other diseases by meshing medical imaging, machine learning and AI. Currently, only about 20% of all cancer patients will actually benefit from immunotherapy, a treatment that differs from chemotherapy in that it uses drugs to help your immune system fight cancer, while chemotherapy uses drugs to directly kill cancer cells, according to the National Cancer Institute.

San Diego (CA) – Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration combines the most advanced artificial intelligence (AI) techniques with a premium integrated drug discovery shared risk platform. The combination of complementary capabilities introduces a new value for companies working in the field, giving them a powerful tool for quick, cost-effective therapeutic product development. "We're pleased to partner with ChemDiv, the leading discovery contract research organization, which built a massive repository of small molecules," said Alex Zhavoronkov, PhD., CEO of Insilico Medicine. "ChemDiv has had a number of highly successful collaborations with pharmaceutical companies in multiple therapeutic areas, moving their discoveries from the unique chemistry idea into the clinic. Together we will improve the novelty, quality and efficiency of preclinical drug discovery and bring our technology and experience to other biotech and pharma partners."

Insilico Medicine, in collaboration with ChemDiv, Inc., launched a drug discovery initiative that aims to use the power of artificial intelligence for screening chemistry space with newly designed compounds. The initiative is expected to identify a massive of drug candidates in the early stages. That became possible because AI can scan a vast number of compounds at higher speeds and with improved accuracy compared to traditional screening projects. The new project is aimed at rapidly screening targets in various therapeutic areas, including oncology, metabolism, immunology, urology, and others. We have successfully identified early drug candidates by screening a limited number of compounds with our AI virtual screening platform.